Dr. Corey S. Goodman Ph.D. is the Independent Exec. Chairman at ALX Oncology.
As the Independent Exec. Chairman of ALX Oncology, the total compensation of Dr D at ALX Oncology is 38,500$. There are 3 executives at ALX Oncology getting paid more, with Dr. Jaume Pons Ph.D. having the highest compensation of 1,280,467$.
Dr D is 70, he's been the Independent Exec. Chairman of ALX Oncology since . There are no older and 7 younger executives at ALX Oncology.
Corey's mailing address filed with the SEC is C/O VENBIO PARTNERS, LLC, 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94010.
Over the last 4 years, insiders at ALX Oncology have traded over 32,891,459$ worth of ALX Oncology stock and bought 1,414,400 units worth 27,854,124$ . The most active insiders traders include G. Walmsley Graham、Jack Nielsen、Capital Ix, Llc Vivo Capita.... On average, ALX Oncology executives and independent directors trade stock every 22 days with the average trade being worth of 89,694$. The most recent stock trade was executed by Shelly Pinto on 14 August 2024, trading 564 units of ALXO stock currently worth 1,455$.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
ALX Oncology executives and other stock owners filed with the SEC include: